The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Conversion effects of PD-1 inhibitor camrelizumab (Cam) combined with Nab-POF regimen in patients (pts) with initially unresectable locally advanced or limited metastatic gastric or gastroesophageal junction adenocarcinoma: FDZL-001 trial.
 
Qirong Geng
No Relationships to Disclose
 
Wanjing Feng
No Relationships to Disclose
 
Hua Huang
No Relationships to Disclose
 
Xiaoying Zhao
No Relationships to Disclose
 
Hong Fu
No Relationships to Disclose
 
Ye Zhou
No Relationships to Disclose
 
Wen Zhang
No Relationships to Disclose
 
Mingzhu Huang
No Relationships to Disclose
 
Guangfa Zhao
No Relationships to Disclose
 
Yanong Wang
No Relationships to Disclose
 
Dazhi Xu
No Relationships to Disclose
 
Weijian Guo
No Relationships to Disclose